Compare MBI & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBI | DRUG |
|---|---|---|
| Founded | 1973 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.2M | 364.8M |
| IPO Year | 1987 | N/A |
| Metric | MBI | DRUG |
|---|---|---|
| Price | $7.53 | $69.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $8.50 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 319.3K | 169.8K |
| Earning Date | 11-04-2025 | 12-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $93,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 285.71 | N/A |
| 52 Week Low | $3.86 | $23.18 |
| 52 Week High | $8.26 | $71.49 |
| Indicator | MBI | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 56.73 | 71.72 |
| Support Level | $7.34 | $56.65 |
| Resistance Level | $7.81 | $60.40 |
| Average True Range (ATR) | 0.27 | 3.76 |
| MACD | -0.01 | 1.16 |
| Stochastic Oscillator | 40.00 | 91.02 |
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.